Objective: Viruses are demonstrated to be an uncommon etiologic agent of early and late pneumonia. In this
study we aimed to investigate the safety and affectivity of
oseltamivir use for viral pneumonia in newborns.
Methods: This was a retrospective study conducted in
a single tertiary neonatal intensive care unit between
September 2009 and April 2013. Demographic, clinical
and laboratory data before and after treatment, duration
of hospitalization, time of clinical improvement were recorded.
Results: During the study period, a total of 69 newborn
cases who were treated by oseltamivir for H1N1 swine
flu (n=12) or suspicious influenza (n=57) were evaluated.
Mean birth weight and gestational age were 3100±601
grams and 37.9±1.8 weeks, respectively. On admission,
median postnatal age was 20.6 (7-47) days. Oseltamivir,
along with supportive care, was administered as 3.0 mg/
kg/dose twice a day for 5 days according to the recommendations of Food and Drug Administration (FDA). The
median time of initiation of oseltamivir was 2.3 days (1-4)
after admission and the median hospitalization day was
10.4 days (5-22). No adverse effects associated with oseltamivir were observed and all patients were discharged
after full recovery.
Conclusion: Oseltamivir use in addition to supportive
therapy seems to be safe and effective in newborns with
severe viral pneumonia.
Key words: Pneumonia, newborn, antiviral treatment